Welcome to AiCuris: The Powerhouse for Anti-infectives    

 

“Committed to making the difference”

AiCuris is a pharmaceutical company focused on the discovery, research and development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.

Founded in 2006 as a spin-out from Bayer's virology and bacteriology research department, AiCuris is now an established “powerhouse for anti-infectives” and is one of the few biotech companies world-wide to have successfully brought a drug to market, and therefore to patients (Prevymis® 2017/18).

Today AiCuris has an innovative pipeline of anti-infective agents and a team of internationally recognized scientists in Research and Development. By focusing on therapeutic areas with high medical need, the company is positioned for growth and success.

 

 

 

 

AiCuris launches “PREP"

AiCuris launches “PREP – Pandemic and Resistance Emergency Preparedness” program at upcoming 4th AMR Conference
  • PREP is a comprephensive four-pillar program to help prevent future pandemics and combat antimicrobial resistance (AMR)
    • Exploring opportunities of AiCuris pipeline products to treat Corona; clinical trial with first drug candidate AIC649 with the potential to become a first-line pandemic therapy under preparation
    • Company commits to driving drug development in resistance breaking antibiotics based on novel scientific approaches
    • AiCuris initiates “AiCubator”, providing long-term support for early but promising research projects in the field of anti-infectives
    • Pursuit of an active licensing strategy for pre-clinical and early clinical projects in the anti-infective space to expand the Company’s portfolio
  • AiCuris to participate in several AMR panels and to discuss partnering opportunities at upcoming virtual 4th AMR Conference

Read more ...

AiCuris joins IMI Consortium against Corona

AiCuris is partner in Europe’s largest initiative to accelerate therapy development for COVID-19 and future Coronavirus threats (CARE)
  • CARE (Corona Accelerated R&D in Europe), supported by Europe’s Innovative Medicines Initiative (IMI), is the largest undertaking of its kind dedicated to discovering and developing urgently needed treatment options for COVID-19.
  • The initiative is committed to a long-term understanding of the disease and development of therapies for COVID-19 and future coronavirus threats in addition to urgent efforts to repurpose existing therapies as potential immediate response.
  • The CARE consortium will accelerate COVID-19 R&D by bringing together the leading expertise and projects of 37 teams from academic and non-profit research institutions and pharmaceutical companies into a comprehensive drug discovery engine.

Read more ...

Breakthrough Therapy Designation

AiCuris was Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir for the Treatment of HSV Infections in Immunocompromised Patients
  • Receiving Breakthrough Therapy Designation will facilitate AiCuris goal of bringing pritelivir to patients as quickly as possible
  • AiCuris is currently preparing to add a pivotal Phase 3 trial part to the ongoing Phase 2 study in immunocompromised patients whose HSV infections have become resistant to acyclovir as a basis for NDA submission
  • The company to discuss partnering opportunities at upcoming BIO Digital

Read more ...